What this Trial Is About

Researchers are evaluating the use of proteomics, metabolomics, and oncofetal chondroitin sulfate-modified proteoglycans as predictors of postoperative complications and biomarkers for colorectal cancer. This observational study focuses on whether these biomarkers can predict anastomotic leakages, cancer recurrence, and serve as diagnostic tests, including identifying biomarkers present in tumor tissue. The study will include patients undergoing elective colorectal surgery or stoma closure. Participants will have elective open or minimally invasive colorectal resections or stoma closures for conditions such as colorectal cancer, inflammatory bowel disease, diverticulitis, or other benign colorectal disorders. Blood samples will be collected daily for up to four days after surgery and at specific intervals up to three years if cancer is diagnosed. Tumor biopsies will be taken during surgery to analyze proteoglycans and other biomarkers. During the study, researchers will collect blood and tissue samples to analyze biomarkers related to postoperative complications, cancer recurrence, and diagnosis. They will monitor outcomes such as anastomotic leakage rates, major complications within 30 days, mortality at 90 days, and cancer recurrence over four years. Data will be gathered from electronic health records, and the study aims to correlate biomarker levels with tumor presence and patient outcomes.

Colorectal Omics and OfCS Proteoglycans